← naar grote beleggers
Affinity Asset Advisors, LLC
vermogensbeheerder · portefeuille $2.21 mld. · 113 posities · rapport per 30.06.2026
Aandelenposities rapport over 30.06.2026, ingediend op 13.08.2026; verandering — t.o.v. 31.03.2026 · 110
| Bedrijf | Aandelen | Waarde | % van de portefeuille | Verandering per kwartaal |
|---|---|---|---|---|
| ROIVANT SCIENCES LTD CUSIP G76279101 | 3 750 000 | $133 mln. | 6.58% | +950 000 |
| APOGEE THERAPEUTICS INC CUSIP 03770N101 | 987 000 | $131 mln. | 6.50% | −297 926 |
| Spyre Therapeutics Inc. US:SYRE | 1 279 134 | $114 mln. | 5.63% | — |
| Xenon Pharmaceuticals Inc US:XENE | 1 595 000 | $96.3 mln. | 4.77% | −80 000 |
| Erasca Inc US:ERAS | 5 250 000 | $96.2 mln. | 4.77% | −100 000 |
| Insmed Inc US:INSM | 650 000 | $69.3 mln. | 3.44% | +170 000 |
| Praxis Precision Medicines I… US:PRAX | 185 000 | $61.9 mln. | 3.07% | +15 000 |
| ALKERMES PLC CUSIP G01767105 | 1 125 000 | $58.9 mln. | 2.92% | −225 000 |
| Oruka Therapeutics, Inc. US:ORKA | 590 000 | $56.2 mln. | 2.78% | +90 327 |
| AnaptysBio Inc US:ANAB | 826 109 | $55.8 mln. | 2.77% | −113 891 |
| Avalo Therapeutics Inc US:AVTX | 2 900 000 | $53.6 mln. | 2.66% | +1 559 160 |
| Cytokinetics Inc US:CYTK | 550 000 | $46.9 mln. | 2.32% | −150 483 |
| Revolution Medicines, Inc. US:RVMD | 250 000 | $46.8 mln. | 2.32% | +150 000 |
| ABIVAX US:ABVX | 330 000 | $44.0 mln. | 2.18% | −75 000 |
| First Tracks Biotherapeutics US:TRAX | 2 032 012 | $40.9 mln. | 2.03% | nieuw |
| Dianthus Therapeutics Inc. US:DNTH | 400 000 | $39.0 mln. | 1.93% | +50 000 |
| Sutro Biopharma US:STRO | 1 172 487 | $38.9 mln. | 1.93% | +102 968 |
| NUVALENT INC CUSIP 670703107 | 275 000 | $34.0 mln. | 1.68% | −25 000 |
| Trevi Therapeutics Inc US:TRVI | 1 800 172 | $33.6 mln. | 1.66% | −200 000 |
| Ovid Therapeutics Inc US:OVID | 10 144 562 | $27.3 mln. | 1.35% | −491 756 |
| Lexeo Therapeutics, Inc. US:LXEO | 5 807 611 | $27.0 mln. | 1.34% | +757 400 |
| Celldex Therapeutics Inc US:CLDX | 700 000 | $26.0 mln. | 1.29% | +200 000 |
| Belite Bio Inc ADR US:BLTE | 165 000 | $25.4 mln. | 1.26% | +100 000 |
| Enliven Therapeutics Inc. US:ELVN | 500 000 | $25.4 mln. | 1.26% | −86 904 |
| FORTE BIOSCIENCES INC CUSIP 34962G208 | 1 145 391 | $24.3 mln. | 1.21% | +133 501 |
| Nurix Therapeutics Inc US:NRIX | 967 620 | $23.5 mln. | 1.16% | — |
| Alto Neuroscience, Inc. US:ANRO | 850 000 | $22.4 mln. | 1.11% | +350 000 |
| Madrigal Pharmaceuticals Inc US:MDGL | 40 000 | $21.5 mln. | 1.07% | −15 000 |
| Protagonist Therapeutics Inc US:PTGX | 172 125 | $21.1 mln. | 1.05% | — |
| Mineralys Therapeutics, Inc. US:MLYS | 750 000 | $20.2 mln. | 1.00% | — |
| Relay Therapeutics Inc US:RLAY | 1 050 000 | $19.6 mln. | 0.97% | +650 000 |
| Sagimet Biosciences Inc. Ser… US:SGMT | 2 497 864 | $19.3 mln. | 0.96% | +1 629 844 |
| Jade Biosciences, Inc. US:JBIO | 840 350 | $18.7 mln. | 0.93% | +200 394 |
| Cogent Biosciences Inc US:COGT | 450 000 | $17.4 mln. | 0.86% | −300 000 |
| Travere Therapeutics Inc US:TVTX | 300 000 | $17.0 mln. | 0.85% | — |
| Cullinan Therapeutics, Inc. US:CGEM | 875 760 | $15.9 mln. | 0.79% | +94 500 |
| Savara Inc US:SVRA | 2 512 153 | $15.5 mln. | 0.77% | — |
| Ideaya Biosciences Inc US:IDYA | 400 000 | $14.9 mln. | 0.74% | nieuw |
| Perspective Therapeutics Inc… US:CATX | 4 214 582 | $14.4 mln. | 0.71% | +1 050 000 |
| Odyssey Therapeutics, Inc. US:ODTX | 766 346 | $14.3 mln. | 0.71% | nieuw |
| HELIX ACQUISITION CORP III CUSIP G4444S107 | 1 250 000 | $13.3 mln. | 0.66% | — |
| Equillium Inc US:EQ | 4 100 000 | $13.1 mln. | 0.65% | +2 873 690 |
| ESTABLISHMENT LABS HLDGS INC CUSIP G31249108 | 148 013 | $12.7 mln. | 0.63% | +48 013 |
| Climb Bio Inc US:CLYM | 972 000 | $12.7 mln. | 0.63% | +272 000 |
| TEVA PHARMACEUTICAL INDS LTD CUSIP 881624209 | 374 000 | $12.7 mln. | 0.63% | −1 026 000 |
| Veradermics, Incorporated US:MANE | 100 000 | $12.3 mln. | 0.61% | +30 000 |
| Arrowhead Pharmaceuticals In… US:ARWR | 150 000 | $12.2 mln. | 0.61% | −50 000 |
| Taysha Gene Therapies Inc US:TSHA | 1 750 000 | $11.9 mln. | 0.59% | +750 000 |
| DAMORA THERAPEUTICS INC CUSIP 36322Q206 | 425 000 | $11.1 mln. | 0.55% | −25 000 |
| Eupraxia Pharmaceuticals Inc… US:EPRX | 1 650 000 | $10.9 mln. | 0.54% | +60 995 |
| Vera Therapeutics Inc US:VERA | 250 000 | $10.7 mln. | 0.53% | — |
| PROQR THRAPEUTICS N V CUSIP N71542109 | 5 543 936 | $10.3 mln. | 0.51% | +3 089 658 |
| NEWAMSTERDAM PHARMA COMPANY CUSIP N62509109 | 275 000 | $9.32 mln. | 0.46% | — |
| Korro Bio, Inc. US:KRRO | 706 904 | $9.32 mln. | 0.46% | — |
| Anteris Technologies Global… US:AVR | 912 397 | $8.99 mln. | 0.45% | — |
| ZURA BIO LTD CUSIP G9TY5A101 | 1 464 303 | $8.64 mln. | 0.43% | −1 100 000 |
| UNIQURE NV CUSIP N90064101 | 175 000 | $8.06 mln. | 0.40% | nieuw |
| ASCENDIS PHARMA A/S CUSIP K08588103 | 30 000 | $8.00 mln. | 0.40% | nieuw |
| iBio, Inc. US:IBIO | 4 007 881 | $7.01 mln. | 0.35% | +900 681 |
| Generate Biomedicines, Inc. US:GENB | 400 000 | $6.75 mln. | 0.33% | +50 000 |
| Tyra Biosciences Inc US:TYRA | 200 012 | $6.39 mln. | 0.32% | −57 500 |
| SOL-GEL TECHNOLOGIES LTD CUSIP M8694L137 | 84 900 | $6.29 mln. | 0.31% | +49 900 |
| SAB Biotherapeutics Inc US:SABS | 1 525 000 | $5.95 mln. | 0.29% | +950 000 |
| MacroGenics Inc US:MGNX | 1 216 606 | $5.62 mln. | 0.28% | +716 606 |
| CRISPR THERAPEUTICS AG CUSIP H17182108 | 100 000 | $5.45 mln. | 0.27% | −50 000 |
| NEWAMSTERDAM PHARMA COMPANY CUSIP N62509117 | 245 000 | $5.34 mln. | 0.26% | — |
| Assembly Biosciences Inc US:ASMB | 190 000 | $5.22 mln. | 0.26% | nieuw |
| Rezolute, Inc. US:RZLT | 1 000 000 | $5.20 mln. | 0.26% | −547 641 |
| Precision BioSciences Inc US:DTIL | 646 576 | $5.08 mln. | 0.25% | +48 630 |
| Hemab Therapeutics Holdings,… US:COAG | 138 030 | $5.07 mln. | 0.25% | nieuw |
| Viridian Therapeutics Inc US:VRDN | 250 000 | $4.59 mln. | 0.23% | — |
| ArriVent BioPharma, Inc. US:AVBP | 125 000 | $4.34 mln. | 0.22% | −50 000 |
| Verrica Pharmaceuticals Inc US:VRCA | 707 338 | $4.33 mln. | 0.21% | — |
| Compass Pathways Plc US:CMPS | 301 183 | $4.26 mln. | 0.21% | −807 300 |
| MBX Biosciences, Inc. US:MBX | 75 000 | $4.14 mln. | 0.21% | −75 000 |
| RESEARCH ALLIANCE CORP III CUSIP G75226103 | 370 000 | $3.96 mln. | 0.20% | nieuw |
| Immunovant, Inc. US:IMVT | 100 000 | $3.85 mln. | 0.19% | — |
| AMANAT ACQUISITION CORP CUSIP G0375M101 | 375 000 | $3.81 mln. | 0.19% | nieuw |
| BIOHAVEN LTD CUSIP G1110E107 | 250 000 | $3.72 mln. | 0.18% | nieuw |
| Faeth Therapeutics, Inc. US:FTH | 144 404 | $3.61 mln. | 0.18% | nieuw |
| Karyopharm Therapeutics Inc. US:KPTI | 312 500 | $3.05 mln. | 0.15% | −187 500 |
| Alector Inc US:ALEC | 1 510 000 | $3.04 mln. | 0.15% | +1 010 000 |
| SpyGlass Pharma, Inc. US:SGP | 131 586 | $2.93 mln. | 0.15% | −118 414 |
| CRINETICS PHARMACEUTICALS IN CUSIP 22663K107 | 75 000 | $2.81 mln. | 0.14% | — |
| OAKTREE ACQUISITION CORP III CUSIP G6717R120 | 250 000 | $2.75 mln. | 0.14% | — |
| JATT II ACQUISITION CORP CUSIP G50765109 | 200 000 | $2.27 mln. | 0.11% | nieuw |
| Neumora Therapeutics, Inc. US:NMRA | 1 070 651 | $1.82 mln. | 0.09% | nieuw |
| Amylyx Pharmaceuticals Inc US:AMLX | 98 999 | $1.78 mln. | 0.09% | nieuw |
| Adlai Nortye Group Ltd. US:ANL | 153 847 | $1.77 mln. | 0.09% | −10 901 |
| Spruce Biosciences, Inc. US:SPRB | 30 000 | $1.62 mln. | 0.08% | nieuw |
| Eikon Therapeutics, Inc. US:EIKN | 98 001 | $1.28 mln. | 0.06% | nieuw |
| OnKure Therapeutics, Inc. US:OKUR | 240 963 | $1.10 mln. | 0.05% | — |
| enGene Therapeutics Inc. US:ENGN | 600 000 | $1.04 mln. | 0.05% | nieuw |
| X4 Pharmaceuticals Inc US:XFOR | 145 000 | $677 k | 0.03% | — |
| Boundless Bio, Inc. US:BOLD | 250 000 | $625 k | 0.03% | nieuw |
| LENZ Therapeutics Inc US:LENZ | 100 000 | $568 k | 0.03% | — |
| Q32 Bio Inc US:QTTB | 27 777 | $354 k | 0.02% | — |
| Orchestra BioMed Holdings In… US:OBIO | 33 400 | $144 k | 0.01% | −369 150 |
| NextCure, Inc. US:NXTC | 41 960 | $67.1 k | 0.00% | −199 866 |
| Adagio Medical Holdings, Inc US:ADGM | 80 000 | $52.1 k | 0.00% | — |
| ROCKET PHARMACEUTICALS INC CUSIP 77313F114 | 75 000 | $278 | 0.00% | — |
| Corcept Therapeutics Incorpo… US:CORT | 0 (was 50 000) | — | — | verkocht |
| ENGENE HOLDINGS INC CUSIP 29286M105 | 0 (was 610 370) | — | — | verkocht |
| KEZAR LIFE SCIENCES INC CUSIP 49372L209 | 0 (was 229 076) | — | — | verkocht |
| TERNS PHARMACEUTICALS INC CUSIP 880881107 | 0 (was 562 631) | — | — | verkocht |
| WAVE LIFE SCIENCES LTD CUSIP Y95308105 | 0 (was 1 401 727) | — | — | verkocht |
| ARCELLX INC CUSIP 03940C100 | 0 (was 362 764) | — | — | verkocht |
| Ascendis Pharma AS US:ASND | 0 (was 95 000) | — | — | verkocht |
| BridgeBio Pharma Inc US:BBIO | 0 (was 150 000) | — | — | verkocht |
| CENTESSA PHARMACEUTICALS PLC CUSIP 152309100 | 0 (was 1 400 000) | — | — | verkocht |
In bedrijven uit onze database 13
| Bedrijf | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| Lexeo Therapeutics, Inc. | 7.08% | 5 807 611 | 2026-06-30 |
| Helix Acquisition Corp. III… | 7.04% | 1 250 000 | 2026-06-30 |
| Equillium Inc | 6.47% | 4 100 000 | 2026-06-30 |
| iBio, Inc. | 6.23% | 4 007 881 | 2026-06-30 |
| Avalo Therapeutics Inc | 5.41% | 2 900 000 | 2026-06-30 |
| Ovid Therapeutics Inc | 5.19% | 10 144 562 | 2026-06-30 |
| Amanat Acquisition Corp Clas… | 4.81% | 375 000 | 2026-06-30 |
| Korro Bio, Inc. | 4.8% | 706 904 | 2026-06-30 |
| Perspective Therapeutics Inc… | 3.69% | 4 214 582 | 2026-06-30 |
| AnaptysBio Inc | 2.76% | 826 109 | 2026-06-30 |
| Sol Gel Technologies Ltd | 2.59% | 84 900 | 2026-06-30 |
| Eupraxia Pharmaceuticals Inc… | 2.54% | 1 650 000 | 2026-06-30 |
| Adagio Medical Holdings, Inc | 0.29% | 80 000 | 2026-06-30 |
advertentie